The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project
N Engl J Med. 2002 346 (25): 1937-47

PMID: 12075054 · DOI:10.1056/NEJMoa012914

MeSH Terms (15)

Antibiotics, Antineoplastic Antineoplastic Combined Chemotherapy Protocols Biopsy Female Gene Expression Profiling Humans Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Male Middle Aged Oligonucleotide Array Sequence Analysis Prognosis Proportional Hazards Models Retrospective Studies Survival Analysis

Connections (1)

This publication is referenced by other Labnodes entities:

Links